1887

Abstract

Purpose. The aim of this study was to compare the in vitro activity of ampicillin and moxifloxacin against six isolates selected from 154 invasive clinical isolates of Listeria monocytogenes and evaluate their intra- and extracellular activities with achievable central nervous system concentrations obtained using Monte Carlo simulations with conventional and unconventional dosages.

Methodology. The MICs and minimal bactericidal concentrations (MBCs) of ampicillin and moxifloxacin were determined by using the broth microdilution method. The intra- and extracellular activities were compared using time–kill curves and inhibition of intracellular growth assays.

Results. The MICs50/90 of ampicillin were 0.125/0.5 mg l and the MBC50/90 was ≥16 mg l, while the moxifloxacin MICs50/90 were 0.25/0.5 mg l and the MBC50/90 was 0.5 mg l. Ampicillin did not show any extracellular bactericidal activity at 24 h, although bactericidal activity was detected at 48 h. For moxifloxacin, the bactericidal effect was evident after 6 h of incubation. Both antibiotics achieved significant reductions in intracellular inoculum after 1–24 h of incubation; however, moxifloxacin becomes bactericidal more rapidly, producing a much greater reduction in the inoculum in the first hour than ampicillin. There were no differences among the MIC and MBC values of moxifloxacin and ampicillin among the strains belonging to different serotypes and/or epidemic clones. This fact was also found in the intra- and extracellular studies.

Conclusion. The results of this study demonstrated the faster bactericidal activity of moxifloxacin at achievable central nervous system concentrations against intra- and extracellular forms of L. monocytogenes in comparison with ampicillin.

Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.000486
2017-06-09
2019-10-22
Loading full text...

Full text loading...

/deliver/fulltext/jmm/66/6/713.html?itemId=/content/journal/jmm/10.1099/jmm.0.000486&mimeType=html&fmt=ahah

References

  1. Doganay M. Listeriosis: clinical presentation. FEMS Immunol Med Microbiol 2003;35:173–175 [CrossRef][PubMed]
    [Google Scholar]
  2. Arslan F, Meynet E, Sunbul M, Sipahi OR, Kurtaran B et al. The clinical features, diagnosis, treatment, and prognosis of neuroinvasive listeriosis: a multinational study. Eur J Clin Microbiol Infect Dis 2015;34:1213–1221 [CrossRef][PubMed]
    [Google Scholar]
  3. Tunkel AR, Hartman BJ, Kaplan SL, Kaufman BA, Roos KL et al. Practice guidelines for the management of bacterial meningitis. Clin Infect Dis 2004;39:1267–1284 [CrossRef][PubMed]
    [Google Scholar]
  4. Lutsar I, Mccracken GH, Friedland IR. Antibiotic pharmacodynamics in cerebrospinal fluid. Clin Infect Dis 1998;27:1117–1127 [CrossRef][PubMed]
    [Google Scholar]
  5. Marget W, Seeliger HP. Listeria monocytogenes infectionstherapeutic possibilities and problems. Infection 1988;16:S175–S177 [CrossRef][PubMed]
    [Google Scholar]
  6. Jones EM, MacGowan AP. Antimicrobial chemotherapy of human infection due to Listeria monocytogenes. Eur J Clin Microbiol Infect Dis 1995;14:165–175 [CrossRef][PubMed]
    [Google Scholar]
  7. Kanellakopoulou K, Pagoulatou A, Stroumpoulis K, Vafiadou M, Kranidioti H et al. Pharmacokinetics of moxifloxacin in non-inflamed cerebrospinal fluid of humans: implication for a bactericidal effect. J Antimicrob Chemother 2008;61:1328–1331 [CrossRef][PubMed]
    [Google Scholar]
  8. Grayo S, Join-Lambert O, Desroches MC, Le Monnier A. Comparison of the in vitro efficacies of moxifloxacin and amoxicillin against Listeria monocytogenes. Antimicrob Agents Chemother 2008;52:1697–1702 [CrossRef][PubMed]
    [Google Scholar]
  9. Grayo S, Lott-Desroches MC, Dussurget O, Respaud R, Fontanet A et al. Rapid eradication of Listeria monocytogenes by moxifloxacin in a murine model of central nervous system listeriosis. Antimicrob Agents Chemother 2008;52:3210–3215 [CrossRef][PubMed]
    [Google Scholar]
  10. Sipahi OR, Turhan T, Pullukcu H, Calik S, Tasbakan M et al. Moxifloxacin versus ampicillin + gentamicin in the therapy of experimental Listeria monocytogenes meningitis. J Antimicrob Chemother 2008;61:670–673 [CrossRef][PubMed]
    [Google Scholar]
  11. Hof H, Fabrig J. Die Wirkung von Gyrase-Hemmern auf Listerien. Fortschr Antimicrob Antineoplast Chemother 1987;6-10:1781–1785
    [Google Scholar]
  12. Lepe JA, Torres MJ, Liró J, Luque R, Aznar J. Caracterización microbiológica de los aislados de Listeria monocytogenes procedentes de casos humanos en Andalucía. Enferm Infecc Microbiol Clin 2012;30:602–607 [CrossRef]
    [Google Scholar]
  13. CLSI Methods for Antimicrobial Dilution and Disk Susceptibility Testing of Infrequently Isolated or Fastidious Bacteria; Approved Guideline—Second Edition CLSI Document M45-A2 Wayne, PA: Clinical and Laboratory Standards Institute; 2010
    [Google Scholar]
  14. CLSI Methods for Determining Bactericidal Activity of Antimicrobial Agents; Approved Guideline CLSI Document M26-A Wayne, PA: Clinical and Laboratory Standards Institute; 1999
    [Google Scholar]
  15. Arias CA, Contreras GA, Murray BE. Management of multidrug-resistant enterococcal infections. Clin Microbiol Infect 2010;16:555–562 [CrossRef][PubMed]
    [Google Scholar]
  16. Thwaites GE, Tran TH. Tuberculous meningitis: many questions, too few answers. Lancet Neurol 2005;4:160–170 [CrossRef][PubMed]
    [Google Scholar]
  17. Blum RA, Kohli RK, Harrison NJ, Schentag JJ. Pharmacokinetics of ampicillin (2.0 grams) and sulbactam (1.0 gram) coadministered to subjects with normal and abnormal renal function and with end-stage renal disease on hemodialysis. Antimicrob Agents Chemother 1989;33:1470–1476 [CrossRef][PubMed]
    [Google Scholar]
  18. Zhu L, Wang N, Yang W, Zhang Y, Zhao X et al. Population pharmacokinetics of intravenous moxifloxacin 400 mg once-daily dosage in infected patients. J Infect Chemother 2014;20:621–626 [CrossRef][PubMed]
    [Google Scholar]
  19. Andes DR, Craig WA. Pharmacokinetics and pharmacodynamics of antibiotics in meningitis. Infect Dis Clin North Am 1999;13:595–618 [CrossRef][PubMed]
    [Google Scholar]
  20. Macgowan AP, Wootton M, Hedges AJ, Bowker KE, Holt HA et al. A new time-kill method of assessing the relative efficacy of antimicrobial agents alone and in combination developed using a representative beta-lactam, aminoglycoside and fluoroquinolone. J Antimicrob Chemother 1996;38:193–203 [CrossRef][PubMed]
    [Google Scholar]
  21. Lepe JA, Torres MJ, Smani Y, Parra-Millán R, Pachón J et al. In vitro and intracellular activities of fosfomycin against clinical strains of Listeria monocytogenes. Int J Antimicrob Agents 2014;43:135–139 [CrossRef][PubMed]
    [Google Scholar]
  22. Hoogkamp-Korstanje JA, Roelofs-Willemse J. Comparative in vitro activity of moxifloxacin against Gram-positive clinical isolates. J Antimicrob Chemother 2000;45:31–39 [CrossRef][PubMed]
    [Google Scholar]
  23. Morvan A, Moubareck C, Leclercq A, Hervé-Bazin M, Bremont S et al. Antimicrobial resistance of Listeria monocytogenes strains isolated from humans in France. Antimicrob Agents Chemother 2010;54:2728–2731 [CrossRef][PubMed]
    [Google Scholar]
  24. Madeo M, Musumeci R, Careddu AM, Amato E, Pontello MM et al. Antimicrobial susceptibility of Listeria monocytogenes isolates from human cases in northern Italy, 2008-2010: MIC determination according to EUCAST broth microdilution method. J Chemother 2015;27:201–206 [CrossRef][PubMed]
    [Google Scholar]
  25. Poulsen PN, Lester A, Andreasen J, Carvajal A. In vitro susceptibility of Listeria monocytogenes isolated from human blood and cerebrospinal fluid. APMIS 1988;96:223–228 [CrossRef]
    [Google Scholar]
  26. Moellering RC, Medoff G, Leech I, Wennersten C, Kunz LJ. Antibiotic synergism against Listeria monocytogenes. Antimicrob Agents Chemother 1972;1:30–34 [CrossRef][PubMed]
    [Google Scholar]
  27. Marklein G. Chemotherapie der Listeriose: in-vitro-studie unter Berücksichtigung neuerer Penicilline und Cephalosporine. DMW - Deutsche Medizinische Wochenschrift 1982;107:415–418 [CrossRef]
    [Google Scholar]
  28. Seral C, Barcia-Macay M, Mingeot-Leclercq MP, Tulkens PM, van Bambeke F. Comparative activity of quinolones (ciprofloxacin, levofloxacin, moxifloxacin and garenoxacin) against extracellular and intracellular infection by Listeria monocytogenes and Staphylococcus aureus in J774 macrophages. J Antimicrob Chemother 2005;55:511–517 [CrossRef][PubMed]
    [Google Scholar]
  29. Carryn S, van Bambeke F, Mingeot-Leclercq MP, Tulkens PM. Activity of β-lactams (ampicillin, meropenem), gentamicin, azithromycin and moxifloxacin against intracellular Listeria monocytogenes in a 24 h THP-1 human macrophage model. J Antimicrob Chemother 2003;51:1051–1052 [CrossRef][PubMed]
    [Google Scholar]
  30. Cherubin CE, Marr JS, Sierra MF, Becker S, Listeria BS. Listeria and Gram-negative bacillary meningitis in New York City, 1972-1979. frequent causes of meningitis in adults. Am J Med 1981;71:199–209[PubMed][CrossRef]
    [Google Scholar]
  31. Appleman MD, Cherubin CE, Heseltine PN, Stratton CW. Susceptibility testing of Listeria monocytogenes. A reassessment of bactericidal activity as a predictor for clinical outcome. Diagn Microbiol Infect Dis 1991;14:311–317 [CrossRef][PubMed]
    [Google Scholar]
  32. Pelletier LL. Lack of reproducibility of macrodilution MBCs for Staphylococcus aureus. Antimicrob Agents Chemother 1984;26:815–818 [CrossRef][PubMed]
    [Google Scholar]
  33. Stratton CW, Liu C, Weeks LS. Activity of LY146032 compared with that of methicillin, cefazolin, cefamandole, cefuroxime, ciprofloxacin, and vancomycin against staphylococci as determined by kill-kinetic studies. Antimicrob Agents Chemother 1987;31:1210–1215 [CrossRef][PubMed]
    [Google Scholar]
  34. Hof H. Chemotherapy of Listeria infections. GMS Infect Dis 2013;1:1–10
    [Google Scholar]
  35. Chin NX, Jules K, Neu HC. Synergy of ciprofloxacin and azlocillin in vitro and in a neutropenic mouse model of infection. Eur J Clin Microbiol 1986;5:23–28 [CrossRef][PubMed]
    [Google Scholar]
  36. Neu HC, Chin NX, Labthavikul P. Antibacterial activity of coumermycin alone and in combination with other antibiotics. Antimicrob Agents Chemother 1984;25:687–689 [CrossRef][PubMed]
    [Google Scholar]
  37. Safdar A, Armstrong D. Antimicrobial activities against 84 Listeria monocytogenes isolates from patients with systemic listeriosis at a comprehensive cancer center (1955-1997). J Clin Microbiol 2003;41:483–485 [CrossRef][PubMed]
    [Google Scholar]
  38. Hof H. Antibiotic treatment of infections with intracellular bacteria. In Paradise LJ, Friedman H, Bendinelli M. (editors) Opportunistic Intracellular Bacteria and Immunity New York: Plenum Press; 1999; pp.281–293
    [Google Scholar]
  39. Michelet C, Avril JL, Cartier F, Berche P. Inhibition of intracellular growth of Listeria monocytogenes by antibiotics. Antimicrob Agents Chemother 1994;38:438–446 [CrossRef][PubMed]
    [Google Scholar]
  40. Sauer JD, Witte CE, Zemansky J, Hanson B, Lauer P et al. Listeria monocytogenes that lyse in the macrophage cytosol trigger AIM2-mediated pyroptosis. Cell Host Microbe 2010;7:412–419[CrossRef]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.000486
Loading
/content/journal/jmm/10.1099/jmm.0.000486
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error